Clinical Trial Update: Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a soluble guanylate cyclase stimulator to improve digital blood flow in Raynaud's phenomenon; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon

Snippet

Sponsor: Bayer | Conditions: Raynaud Disease | Phase 2 | Status: COMPLETED